Literature DB >> 27069014

Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy.

J M Pitt1, A Marabelle2, A Eggermont3, J-C Soria4, G Kroemer5, L Zitvogel6.   

Abstract

The tumor microenvironment (TME) is an integral part of cancer. Recognition of the essential nature of the TME in cancer evolution has led to a shift from a tumor cell-centered view of cancer development to the concept of a complex tumor ecosystem that supports tumor growth and metastatic dissemination. Accordingly, novel targets within the TME have been uncovered that can help direct and improve the actions of various cancer therapies, notably immunotherapies that work by potentiating host antitumor immune responses. Here, we review the composition of the TME, how this attenuates immunosurveillance, and discuss existing and potential strategies aimed at targeting cellular and molecular TME components.
© The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  angiogenesis; anticancer therapy; cancer; immunosuppression; immunotherapy; tumor microenvironment

Mesh:

Year:  2016        PMID: 27069014     DOI: 10.1093/annonc/mdw168

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  242 in total

Review 1.  Resistance to immunotherapy: clouds in a bright sky.

Authors:  Gérard Milano
Journal:  Invest New Drugs       Date:  2017-04-12       Impact factor: 3.850

Review 2.  Integrative Pharmacology: Advancing Development of Effective Immunotherapies.

Authors:  Mohammad Tabrizi; Daping Zhang; Vaishnavi Ganti; Glareh Azadi
Journal:  AAPS J       Date:  2018-04-27       Impact factor: 4.009

3.  The Proteomic Effects of Pulsed Focused Ultrasound on Tumor Microenvironments of Murine Melanoma and Breast Cancer Models.

Authors:  Omer Aydin; Parwathy Chandran; Rebecca R Lorsung; Gadi Cohen; Scott R Burks; Joseph A Frank
Journal:  Ultrasound Med Biol       Date:  2019-09-14       Impact factor: 2.998

4.  Blockade of TNFR2 signaling enhances the immunotherapeutic effect of CpG ODN in a mouse model of colon cancer.

Authors:  Yingjie Nie; Jiang He; Hidekazu Shirota; Anna L Trivett; Dennis M Klinman; Joost J Oppenheim; Xin Chen
Journal:  Sci Signal       Date:  2018-01-02       Impact factor: 8.192

Review 5.  Epigenetic control of the tumor microenvironment.

Authors:  David L Marks; Rachel Lo Olson; Martin E Fernandez-Zapico
Journal:  Epigenomics       Date:  2016-10-04       Impact factor: 4.778

6.  Local Activation of p53 in the Tumor Microenvironment Overcomes Immune Suppression and Enhances Antitumor Immunity.

Authors:  Gang Guo; Miao Yu; Wei Xiao; Esteban Celis; Yan Cui
Journal:  Cancer Res       Date:  2017-03-09       Impact factor: 12.701

7.  Partially exhausted tumor-infiltrating lymphocytes predict response to combination immunotherapy.

Authors:  Kimberly Loo; Katy K Tsai; Kelly Mahuron; Jacqueline Liu; Mariela L Pauli; Priscila M Sandoval; Adi Nosrati; James Lee; Lawrence Chen; Jimmy Hwang; Lauren S Levine; Matthew F Krummel; Alain P Algazi; Miguel Pampaloni; Michael D Alvarado; Michael D Rosenblum; Adil I Daud
Journal:  JCI Insight       Date:  2017-07-20

8.  Neutrophil-to-Lymphocyte Ratio After Definitive Concurrent Chemoradiotherapy Predicts Survival in Patients With Esophageal Squamous Cell Carcinoma.

Authors:  Hyeon Kang Koh; Younghee Park; Taeryool Koo; Hae Jin Park; Me Yeon Lee; Ah Ram Chang; Semie Hong; Hoonsik Bae
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

Review 9.  Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy.

Authors:  Anne M Macpherson; Simon C Barry; Carmela Ricciardelli; Martin K Oehler
Journal:  J Clin Med       Date:  2020-09-14       Impact factor: 4.241

10.  Systemic immune responses are associated with molecular characteristics of circulating tumor cells in head and neck squamous cell carcinoma.

Authors:  Hiroe Tada; Yurino Nagata; Hideyuki Takahashi; Toshiyuki Matsuyama; Shota Ida; Ikko Mito; Kazuaki Chikamatsu
Journal:  Mol Clin Oncol       Date:  2021-05-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.